AKAndreas Karachristos

Andreas Karachristos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas Karachristos has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma

    by Taylor L. Garza, Jae Hwan Choi, Michelle McGee, Edmond Box, Timothy Nywening, Andreas Karachristos, Abraham Schwarzberg, Mayer Fishman, Richard Jacobson

    Roughly 100,000 new cases of melanoma are diagnosed yearly in the United States, the majority of which are early-stage disease with excellent prognosis. However, a subset of patients harbors clinically occult aggressive biology that can go undetected on standard clinicopathologic analyses. Gene expression profiling (GEP) assays have emerged as molecular adjuncts to risk stratification, aiming to improve sentinel lymph node biopsy (SLNB) decision-making and surveillance planning. Two commercial tests are widely available: the 31-gene expression profile (31-GEP, DecisionDx-Melanoma, Castle Biosciences) and the clinicopathologic gene expression profile (CP-GEP, Merlin, SkylineDx). This review summarizes the current evidence for each assay regarding their performance and utility, with a focus on potentially actionable use cases, limitations, and the practical context in which these tools are most valuable.

  • Open Access

    Leiomyosarcoma of the left kidney with renal vein and inferior vena cava tumor thrombus

    by Austin Erickson, Aleksander Druck, Andreas Karachristos, Trushar Patel

  • Surgical Management of Pancreatic Neuroendocrine Tumors (PNET)

    by Candace Gonzalez, Anthony DeSantis, Meagan Read, Andreas Karachristos

  • Obesity affects outcomes of pancreatoduodenectomy

    by KonstantinosA. Zorbas, Jingwei Wu, SanjayS. Reddy, NestorF. Esnaola, Andreas Karachristos


  • Open Access

    The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer

    by Jennifer B. Permuth, Kaleena B. Dezsi, Shraddha Vyas, Karla N. Ali, Toni L. Basinski, Ovie A. Utuama, Jason W. Denbo, Jason Klapman, Aamir Dam, Estrella Carballido, et al.

    Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective cohort study and biorepository designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). We provide an overview of stakeholders; study eligibility and design; recruitment strategies; standard operating procedures to collect, process, store, and transfer biospecimens, medical images, and data; our cloud-based data management platform; and progress regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and questionnaires (62%). Conclusions: This biorepository addresses a critical gap in PaCa research and has potential to advance translational studies intended to minimize disparities and reduce PaCa-related morbidity and mortality.


  • Surgical Management of Pancreatic Neuroendocrine Tumors (PNET)

    by Candace Gonzalez, Anthony DeSantis, Meagan Read, Andreas Karachristos

  • Open Access

    Modified frailty index predicts complications and death after non-bariatric gastrectomies

    by Konstantinos A. Zorbas, Vic Velanovich, Nestor F. Esnaola, Andreas Karachristos

    Background: The modified frailty index (mFI) has been shown to predict mortality and morbidity after major operations. The aim of the present study was to assess the mFI as a preoperative predictor of short-term postoperative complications and 30-day mortality in patients undergoing gastrectomy for non-bariatric diseases. Methods: The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database was queried for patients who underwent total or partial gastrectomy from 2005 to 2011. A mFI was calculated based on 11 variables as previously described. The population divided into the following four categories based on the mFI score: the non-frail (mFI 0), the low frail (mFI 1), the intermediate frail (mFI 2) and frail (mFI ≥3). Thirty-day mortality and postoperative complications were evaluated. Results: Overall, 5,711 patients underwent a gastrectomy for non-bariatric diseases. Higher mFI score was associated with higher rates of mortality (from 1.2% in the non-frail group to 10.7% in frail group, Pvs. 51.1%, Pvs. 24.6%, Pvs. 42.6%, Pvs. 16.4%, Pvs. 20.7%, Pvs. 21.8%, PConclusions: Higher mFI score in patients undergoing non-bariatric gastrectomy, is associated with a stepwise greater risk of postoperative morbidity and mortality. MFI Score can be easily calculated preoperatively, from the patient’s history, and it can be used as an exceptionally useful criterion for treatment planning.


  • Open Access

    The Florida Pancreas Collaborative Next-Generation Biobank: State-wide Infrastructure to Reduce Disparities and Improve Survival for a Racially and Ethnically Diverse Cohort of Patients with Pancreatic Cancer

    by Jennifer B. Permuth, Kaleena B. Dezsi, Shraddha Vyas, Karla N. Ali, Toni L. Basinski, Ovie A. Utuama, Jason W. Denbo, Jason Klapman, Aamir Dam, Estrella Carballido, et al.

    Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research and discovery. However, most biorepositories have poor representation of minority groups, limiting the ability to address cancer health disparities and improve disease outcomes. This report describes the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective longitudinal cohort study and biorepository specifically designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). Methods: We describe rationale for establishing the FPC and provide an overview of key stakeholders; study eligibility and design; ascertainment and recruitment strategies; and standard operating procedures (SOPs) developed to collect, process, store, and transfer biospecimens, medical images, and data. We also describe the customized cloud-based, secure data management platform built to facilitate recruitment, track study-related workflow, house data, and perform queries. We also present progress to date regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for study eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and baseline questionnaire data (62%). Conclusions: This biorepository addresses a critical gap in PaCa research with the potential to advance basic, clinical, population-based, and translational studies intended to minimize disparities, increase quality of life, and reduce PaCa-related morbidity and mortality. Impact: This multi-institutional infrastructure can serve as a prototype for development of similar resources across the country and disease sites.

  • Chylous Ascites After Liver Transplant: Case Report and Review of Literature

    by Amar Nath Mukerji, Esther Tseng, Andreas Karachristos, Manoj Maloo, Ashokkumar Jain

    A 62-year-old man with cirrhosis, hepatitis C, and hepatocellular carcinoma, underwent a liver transplant. On day 11 after surgery, a chylous leak from a partial wound dehiscence was noted. The leak did not respond to 2 weeks of uninterrupted, fat-free clear liquid diet and 12-hour total parenteral nutrition at night. The same treatment was continued for another 6 weeks with fatty meal challenge every weekend, which he failed. He was then given a fat-free clear liquid diet, 24-hour total parenteral nutrition, and octreotide 100 μg subcutaneously every 8 hours for 14 days. A prompt response was noted. His recovery was excellent at the time of this writing (9 months' follow-up). Eleven major cases have been reported with 9 cases being managed conservatively. Four were given a diet plus total parenteral nutrition without octreotide producing a cure in 3 to 36 days. Two cases (including ours) were given the diet and total parenteral nutrition, which failed; octreotide was then added, and these cases were cured in 2 to 4 weeks. Therefore, diet with total parenteral nutrition failed in 33.3% of the cases (2/6). In 3 cases, octreotide was used from the outset. They were all cured in ≤ 2 weeks. One case was operated on for peritonitis; chylous ascites was found and a leak was ligated. One patient with congenital lymphatic disorder underwent peritoneovenous shunting. Octreotide was not used in any of the cases of chylous ascites that were treated surgically. If exploratory surgery is done for any other reason, it is best to identify a chylous leak and ligate it. Otherwise, we recommend octreotide combined with a fat-free, clear liquid diet, and supplementation with medium chain triglycerides and total parenteral nutrition from the outset.